# To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Source: https://onco.cc/trials/nct06756269/  
OnCo record `nct06756269` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Medium dose for 15-HPV vaccine in advanced solid tumours, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.

## Summary

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years is a phase 2 interventional study registered as NCT06756269 by Shanghai Bovax Biotechnology Co., Ltd., with 330 participants planned, started 2025-01-15 and due to reach its primary completion in 2025-10-30. Interventions recorded: Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo and 9-HPV vaccine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06756269
- Phase: 2
- Setting: A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years
- Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- Enrolled: 330

## Sources

- ClinicalTrials.gov NCT06756269: https://clinicaltrials.gov/study/NCT06756269

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06756269.json